Characteristic | Age ≤55 years | Age >55 years | Total | Significance |
---|---|---|---|---|
Sample numbers | 110 (15.2 %) | 613 (84.8 %) | 723 (100 %) | X2 = 349.9, p < 0.001 |
Age (years) | ||||
-Median | 53 | 64 | 63 | |
-Range | 41–55 | 56–79 | 41–79 | |
-Mean | 52.0 | 64.2 | 62.4 | |
PSA score (ng/mL) | ||||
<3 | 11 (10.0 %) | 67 (10.9 %) | 78 (10.8 %) | X2 = 0.08, p = 0.77 |
3–4 | 25 (22.7 %) | 43 (7.0 %) | 68 (9.4 %) | X2 = 27.02, p < 0.001 |
4.1–10 | 62 (56.4 %) | 402 (65.6 %) | 464 (64.2 %) | X2 = 3.45, p = 0.06 |
10.1–20 | 7 (6.4 %) | 90 (14.7 %) | 94 (13.4 %) | X2 = 5.56, p = 0.02 |
>20.1 | 4 (3.6 %) | 8 (1.3 %) | 12 (1.7 %) | X2 = 3.11, p = 0.08 |
Missing | 1 (0.9 %) | 3 (0.5 %) | 4 (0.6 %) | X2 = 0.30, p = 0.59 |
Continuous variable | 110 | 613 | 723 | (t = −0.365, p = 0.72, mean difference = −0.29, 95 % CI of difference = −1.86 to 1.28) |
Gleason score | ||||
3 + 3 | 26 (23.6 %) | 96 (15.7 %) | 122 (16.9 %) | X2 = 4.23, p = 0.40 |
3 + 4 | 57 (51.8 %) | 326 (53.2 %) | 383 (53.0 %) | X2 = 0.70, p = 0.79 |
4 + 3 | 19 (17.3 %) | 128 (20.9 %) | 147 (20.3 %) | X2 = 0.75, p = 0.39 |
8 | 3 (2.7 %) | 13 (2.1 %) | 16 (2.2 %) | X2 = 0.16, p = 0.69 |
9–10 | 5 (4.5 %) | 50 (8.2 %) | 55 (7.6 %) | X2 = 1.73, p = 0.19 |
>6 | 84 (76.4 %) | 517 (84.3 %) | 601 (83.1 %) | X2 = 4.23, p = 0.40 |
>7 | 8 (7.3 %) | 63 (10.3 %) | 71 (9.8 %) | X2 = 0.95, p = 0.33 |
Continuous variable | mean = 2.13 | mean = 2.34 | t = −2.00 | |
Std dev = 0.96 | Std dev = 1.04 | p = 0.05 | ||
Mean difference = −0.212 | ||||
95 % CI of difference = −0.42 to 0.00 | ||||
Pathological stage | ||||
pT2 | 72 (65.5 %) | 365 (59.5 %) | 437 (60.4 %) | X2 = 1.36, p = 0.24 |
pT3a | 24 (21.8 %) | 167 (27.2 %) | 191 (26.4 %) | X2 = 1.41, p = 0.24 |
pT3b | 14 (12.7 %) | 80 (13.1 %) | 94 (13.0 %) | X2 = 0.01, p = 0.93 |
pT4 | 0 (0 %) | 0 (0 %) | 0 (0 %) | - |
Missing | 0 (0 %) | 1 (0.2 %) | 1 (0.1 %) | X2 = 0.18, p = 0.67 |
Prostate weight | Mean = 46.40 | Mean = 54.83 | t = −5.11, | |
Std dev = 14.86 | Std dev = 20.72 | df = 191.8, | ||
p < 0.001, | ||||
95 % CI = −11.69 to −5.17 | ||||
Tumour volume | ||||
<0.5 | 21 (19.1 %) | 109 (17.8 %) | 130 (18.0 %) | X2 = 0.11, p = 0.74 |
0.5-1 | 23 (20.9 %) | 107 (17.5 %) | 130 (18.0 %) | X2 = 0.75, p = 0.39 |
1.1-2 | 17 (15.5 %) | 106 (17.3 %) | 123 (17.0 %) | X2 = 0.22, p = 0.64 |
2.1+ | 13 (11.8 %) | 123 (20.1 %) | 136 (18.8 %) | X2 = 4.15, p = 0.04 |
Missing | 36 (32.7 %) | 168 (27.4 %) | 204 (28.2 %) | X2 = 1.30, p = 0.25 |
Mean tumour volume | Mean = 1.37 | Mean = 1.82 | t = −1.628, | |
Std dev = 1.51 | Std dev = 2.34 | df = 516, | ||
p = 0.104, | ||||
95 % CI = −1.01 to 0.95 | ||||
Seminal vesicle | ||||
Negative | 102 (92.7 %) | 566 (92.3 %) | 668 (92.4 %) | X2 = 0.02, p = 0.89 |
Positive | 8 (7.3 %) | 47 (7.7 %) | 55 (7.6 %) | |
Lymph nodes | ||||
Negative | 69 (62.7 %) | 384 (62.6 %) | 453 (62.7 %) | X2 = 0.00, p = 0.99 |
Positive | 4 (3.6 %) | 16 (2.2 %) | 20 (2.8 %) | X2 = 0.37, p = 0.55 |
Not taken | 37 (33.6 %) | 213 (29.5 %) | 250 (34.6 %) | X2 = 0.05, p = 0.82 |
Insignificant prostate cancer (Stamey criteria) | 10 (9.1 %) | 40 (6.5 %) | 50 (6.9 %) | X2 = 1.25, p = 0.26 |
Missing | 10 (9.1 %) | 29 (4.7 %) | 39 (5.4 %) | |
Total | 110 | 613 | 723 | |
Clinical stage | ||||
-Organ confined (pT2, N0NX) | 72 (65.5 %) | 363 (59.3 %) | 435 (60.2 %) | X2 = 1.47, p = 0.23 |
-Non-Organ confined (pT3/4, N0-1) | 38 (34.5 %) | 249 (40.7 %) | 287 (39.8 %) | |
Margin positive | 27 (24.5 %) | 156 (25.4 %) | 183 (25.3 %) | X2 = 0.40, p = 0.84 |
High risk PCa | ||||
GS > 7 | 8 (7.3 %) | 63 (10.3 %) | 71 (9.8 %) | X2 = 0.95, p = 0.33 |
PSA > 20 | 4 (3.6 %) | 8 (1.3 %) | 12 (1.7 %) | X2 = 3.11, p = 0.08 |
Clinical stage > T2b | 15 (13.6 %) | 89 (14.5 %) | 104 (14.4 %) | X2 = 0.06, p = 0.81 |
At least one feature of high risk PCa | 22 (20.0 %) | 147 (24.0 %) | 169 (23.4 %) | X2 = 0.83, p = 0.36 |